Skip to main content

Advertisement

SpringerLink
Log in

Reply to “Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19”

  • Letter
  • Published:
Angiogenesis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kow CS, Ramachandram DS, Hasan SS (2022) The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. J Infect Chemother 28(2):257–265. https://doi.org/10.1016/j.jiac.2021.11.008

    Article  CAS  PubMed  Google Scholar 

  2. Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, Alomran F, Alayed K, Alsheef M, AlSumait F et al (2021) Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 375:n2400. https://doi.org/10.1136/bmj.n2400

    Article  PubMed  Google Scholar 

  3. Investigators REMAP-CAP, Investigators ACTIV-4a, Investigators ATTACC, Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN et al (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 385:790–802. https://doi.org/10.1056/NEJMoa2105911

    Article  Google Scholar 

  4. Zuily S, Lefèvre B, Sanchez O, Empis de Vendin O, de Ciancio G, Arlet JB, Khider L, Terriat B, Greigert H, Robert CS et al (2023) Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial. EClinicalMedicine 60:102031. https://doi.org/10.1016/j.eclinm.2023.102031

    Article  PubMed  PubMed Central  Google Scholar 

  5. Dixon B, Smith RJ, Campbell DJ, Moran JL, Doig GS, Rechnitzer T, MacIsaac CM, Simpson N, van Haren FMP, Ghosh AN et al (2021) Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 9:360–372. https://doi.org/10.1016/S2213-2600(20)30470-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Wu X, Xiang M, Jing H, Liu L, Wang C, Novakovic VA, Shi J (2023) Early antithrombotic therapy for another highly lethal viral pneumonia pandemic. Clin Microbiol Infect 29(3):284–287. https://doi.org/10.1016/j.cmi.2022.11.008

    Article  CAS  PubMed  Google Scholar 

  7. Duijvelaar E, Schippers JR, Smeele PJ, de Raaf MA, Vanhove ALEM, Blok SG, Counter COVID Collaborative Group, Twisk JWR, Vonk Noordegraaf A, de Man FS et al (2022) Long-term clinical outcomes of COVID-19 patients treated with imatinib. Lancet Respir Med 10(4):e34–e35. https://doi.org/10.1016/S2213-2600(22)00052-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Atmowihardjo LN, Schippers JR, Duijvelaar E, Bartelink IH, Bet PM, Swart NEL, van Rein N, Purdy K, Cavalla D, McElroy A et al (2023) Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial. Crit Care 27(1):226. https://doi.org/10.1186/s13054-023-04516-4

    Article  PubMed  PubMed Central  Google Scholar 

  9. Morales-Ortega A, Farfán-Sedano AI, San Martín-López JV, Escribá-Bárcena A, Jaenes-Barrios B, Madroñal-Cerezo E, Llarena-Barroso C, Mesa-Plaza N, Frutos-Pérez B, Ruiz-Giardín JM et al (2023) Baricitinib or imatinib in hospitalized COVID-19 patients: results from COVINIB, an exploratory randomized clinical trial. J Med Virol 95(2):e28495. https://doi.org/10.1002/jmv.28495

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, The First Hospital, Harbin Medical University, Harbin, 150001, China

    Xiaoming Wu & Jialan Shi

  2. Department of Research, VA Boston Healthcare System, Harvard Medical School, Boston, MA, 02215, USA

    Jialan Shi

  3. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA

    Jialan Shi

Authors
  1. Xiaoming Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jialan Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors analyzed the content of the letter (Kow et al.), engaged in extensive discussions, and participated in the writing of the manuscript.

Corresponding author

Correspondence to Jialan Shi.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, X., Shi, J. Reply to “Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19”. Angiogenesis 26, 485–486 (2023). https://doi.org/10.1007/s10456-023-09894-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10456-023-09894-5

Search

Navigation